| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 10.6 | 9.0 |
| Profit before tax | -42.8 | -68.8 |
| Net income | -40.8 | -57.1 |
| EPS (diluted, $ a share) | $-0.13 | $-0.19 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +18.8% |
|---|
10-Q filed with the SEC, NASDAQ: ABCL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
AbCellera Biologics Inc.: key numbers
- Share price
- $11.12Close, Nov 16
- Market cap
- $3.63B
- Shares outstanding
- 326.62MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from AbCellera Biologics Inc.
All →AbCellera Biologics CFO Andrew Booth Buys $97.4K of Stock
Andrew Booth, CFO, bought 8,600 shares of AbCellera Biologics Inc. at $11.33 a share, worth $97.4K in total on Nov 13, 2026. Shares held after the trade: 491,400 (+1.8%).
- Value
- $97.4K
- Shares
- 8,600
- Price
- $11.33
- Role
- CFO
- Holding change
- +1.8%
- Trade date
- Nov 13, 2026
AbCellera Biologics Insider Thermopylae Holdings Ltd. Buys $699K of Stock
Thermopylae Holdings Ltd. bought 60,565 shares of AbCellera Biologics Inc. at $11.54 a share, worth $699K in total on Nov 12, 2026. Shares held after the trade: 56,194,662 (+0.1%).
- Value
- $699K
- Shares
- 60,565
- Price
- $11.54
- Holding change
- +0.1%
- Trade date
- Nov 12, 2026
AbCellera Biologics Financial Results
AbCellera reported Q3 2026 financial results with revenue of $10.6 million and a net loss of $40.8 million. The company highlighted positive Phase 2 data for its ABCL635 program and a $200 million capital raise that increased total liquidity to approximately $890 million.
- Term
- Q3 2026
“This was a transformative quarter for AbCellera, highlighted by strong clinical execution and balance sheet expansion. Positive top-line Phase 2 results for ABCL635 demonstrated an efficacy and tolerability profile that has potential to redefine the treatment of hot flashes.”
Carl Hansen, Ph.D., founder and CEO of AbCellera
“On the strength of this data, we raised $200 million, bringing our available liquidity to approximately $900 million. Together with the top-line Phase 1 readout of ABCL575 and the addition of three new pipeline programs, ABCL992, ABCL385, and ABCL646, we have delivered on all corporate priorities for 2026.”
Carl Hansen, Ph.D., founder and CEO of AbCellera